Urine Biomarker for Kidney Transplant Rejection
Launched by EXOSOME DIAGNOSTICS, INC. · Oct 8, 2021
Trial Information
Current as of July 22, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at a special test that might help doctors understand if a kidney transplant is being rejected by the body. When someone receives a kidney transplant, it's crucial to monitor how well the body accepts the new organ. This study will collect urine samples to see if certain markers in the urine can indicate whether a transplant is being rejected.
To join this study, participants need to be adults aged 65 to 74 who have already received a kidney transplant and can give their consent to participate. Unfortunately, children under 18 are not eligible for this trial. Those who take part will provide urine samples at various times, helping researchers learn more about kidney transplant rejection and improve future care for patients. The trial is not yet recruiting participants, so more information will be available when it starts.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Ability to provide informed consent
- • Kidney Transplant
- Exclusion Criteria:
- • Pediatric patients, under 18 years of age
About Exosome Diagnostics, Inc.
Exosome Diagnostics, Inc. is a pioneering biotechnology company focused on advancing the field of precision medicine through the development of innovative diagnostic solutions. Specializing in the isolation and analysis of exosomes—nanovesicles that play a crucial role in intercellular communication—Exosome Diagnostics aims to transform the way diseases are diagnosed and monitored. By leveraging its proprietary technologies, the company is dedicated to providing non-invasive, liquid biopsy testing that enhances clinical decision-making and improves patient outcomes across various therapeutic areas, including oncology and neurology. With a commitment to scientific excellence and collaboration, Exosome Diagnostics is at the forefront of developing next-generation biomarkers that hold the potential to revolutionize disease management.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Sonia Kumar
Study Chair
Exosome Diagnostics, Inc.
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials